Literature DB >> 3923693

Two techniques for detection of antibodies against Corynebacterium (Rhodococcus) equi in horse sera.

B Skalka, A Svastová.   

Abstract

Two techniques were developed to detect antibodies against the exosubstance of C. equi called equi-factor. In the first technique serum samples are tested against native equi-factor produced by the growth of C. equi on agar medium. A positive result is manifested by the development of precipitation lines. The second test is based on neutralization of prepurified equi-factor by antibody, resulting in the inhibition of its hemolytic synergism with staphylococcal beta toxin. Sera (125 samples) from horses of different ages, kept in localities with a history of C. equi infections, were examined. The first technique detected 65.6%, and the second 40% of positive cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923693     DOI: 10.1016/0378-1135(85)90055-0

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  4 in total

Review 1.  Rhodococcus equi: an animal and human pathogen.

Authors:  J F Prescott
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

2.  Polymorphisms in equine immune response genes and their associations with infections.

Authors:  Petr Horín; Jirrí Smola; Ján Matiasovic; Mirko Vyskocil; Ludmila Lukeszová; Katarína Tomanová; Petr Králík; Vladimír Glasnák; Dana Schröffelová; Ales Knoll; Markéta Sedlinská; Leona Krenková; Petr Jahn
Journal:  Mamm Genome       Date:  2004-10       Impact factor: 2.957

3.  Antibody response of horses to Rhodococcus equi antigens.

Authors:  J M Chirino-Trejo; J F Prescott
Journal:  Can J Vet Res       Date:  1987-07       Impact factor: 1.310

4.  Prevention of foal mortality due to Rhodococcus equi pneumonia on an endemically affected farm.

Authors:  J F Prescott; R Machang'u; J Kwiecien; K Delaney
Journal:  Can Vet J       Date:  1989-11       Impact factor: 1.008

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.